Peptide stacks · Growth hormone
CJC-1295 with DAC and ipamorelin stack: what’s in it and the evidence
Checked against our library and study pagesPublished by PepVault
The CJC-1295 with DAC and ipamorelin stack is two compounds run side by side, each from its own vial or form: CJC-1295 with DAC and ipamorelin. The library records CJC-1295 with DAC at 1–2 mg and ipamorelin at 200–300 mcg per dose as reference ranges.
This page describes what the crowd runs and what a vial holds. It recommends no stack and names no seller.
What’s in the CJC-1295 with DAC and ipamorelin stack
| Part | Reference range | Filed under | Evidence (library) |
|---|---|---|---|
| CJC-1295 with DAC | 1–2 mg | Sustained GH, Weekly dosing, IGF-1 elevation | Moderate |
| Ipamorelin | 200–300 mcg | GH release, Sleep quality, Recovery | Moderate |
The library’s reference range per dose, part by part
CJC-1295 with DAC
CJC-1295 with DAC is one of the two parts of the CJC-1295 with DAC and ipamorelin stack. A long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue.
Ipamorelin
Ipamorelin is one of the two parts of the CJC-1295 with DAC and ipamorelin stack. Considered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides.

Has the CJC-1295 with DAC and ipamorelin stack been studied as a combination?
None of our 436 study pages tested CJC-1295 with DAC and ipamorelin together, so the CJC-1295 with DAC and ipamorelin stack rests on studies of its parts and on community reports.
The studies of the parts, one by one: 5 study pages on CJC-1295 with DAC (3 in people) and 10 study pages on ipamorelin (1 in people).
| Part | Study pages | In people | Strongest study page |
|---|---|---|---|
| CJC-1295 with DAC | 5 | 3 | CJC-1295 with DAC: one shot raised GH 2- to 10-fold in healthy adults (randomized trial, 2006) |
| Ipamorelin | 10 | 1 | Ipamorelin did not speed first meal after bowel surgery vs placebo (randomized trial, 2014) |
What people commonly report on the CJC-1295 with DAC and ipamorelin stack
The library holds no report of what people notice on the CJC-1295 with DAC and ipamorelin stack as a pair. What it records for each part on its own:
- CJC-1295 with DAC: water retention and puffiness, sometimes tingling hands, over the first weeks, and tiredness in the days after the shot.
- Ipamorelin: deeper sleep and vivid dreams first, then better recovery, skin quality and gradual body-composition changes, with milder hunger than GHRP-6.
These are reports from people who run it, collected in the library, not results from a trial and not a promise of what any one person will notice.
Why these are combined
The library’s note on the pair (clinical data)
CJC-1295 WITH DAC stays elevated for days, so the sharp fasted-timing rules of the no-DAC version relax — the GH baseline is continuous rather than pulsed. Ipamorelin still adds the acute pulse on top.
How the parts of the CJC-1295 with DAC and ipamorelin stack are mixed and taken
The CJC-1295 with DAC and ipamorelin stack isn’t one pre-mixed vial in the library: each part has its own route and schedule, as its entry records them.
| Part | Route | How often | Our vial pages |
|---|---|---|---|
| CJC-1295 with DAC | SubQ injection | Weekly | 10 mg vial |
| Ipamorelin | SubQ injection, IM injection | 2–3x daily, best fasted or before bed | 5 mg vial |
Our vial pages work out the mix for each part’s own vial, size by size:
Compared with running the parts apart
The library’s notes on the CJC-1295 with DAC and ipamorelin stack don’t compare it with running either part on its own.
Safety notes
The library holds no combination safety note on the CJC-1295 with DAC and ipamorelin stack, so each part’s own notes apply, on its compound page.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Questions people ask
What is in the CJC-1295 with DAC and ipamorelin stack?
The CJC-1295 with DAC and ipamorelin stack is two compounds run side by side, each from its own vial or form: CJC-1295 with DAC and ipamorelin. The library records CJC-1295 with DAC at 1–2 mg and ipamorelin at 200–300 mcg per dose as reference ranges.
Has the CJC-1295 with DAC and ipamorelin stack been studied together?
Not as a combination in any of our study pages: the CJC-1295 with DAC and ipamorelin stack rests on studies of its parts and on community reports.
Do the parts of the CJC-1295 with DAC and ipamorelin stack come in one vial?
No: in the library each part of the CJC-1295 with DAC and ipamorelin stack is its own compound with its own route and schedule (CJC-1295 with DAC by SubQ injection and ipamorelin by SubQ injection).
What does each part of the CJC-1295 with DAC and ipamorelin stack do?
CJC-1295 with DAC: A long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue. Ipamorelin: Considered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides.